on-randomised trial of a lipid lowering drug and a steroid for the treatment of relapsed Burkitt's lymphoma in Blantyre, Malawi
Completed
- Conditions
- Burkitt's lymphomaCancerDiffuse non-Hodgkin's lymphoma
- Registration Number
- ISRCTN34303497
- Lead Sponsor
- niversity of Malawi (Malawi)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
1. Aged less than 14 years, either sex
2. Diagnosis of relapsed Burkitt's lymphoma confirmed by cytology/immunophenotyping
3. Negative pregnancy test if the patient is of childbearing potential
4. Informed consent, and the ability of the guardian and patient to co-operate with treatment and follow up must be ensured and documented
Exclusion Criteria
1. Patient unable to swallow tablets
2. Patients living outside Malawi (follow up is not possible for patients living in Mozambique)
3. Pregnancy
4. Breast feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Response of Burkitt's lymphoma in the first week of trial therapy<br>2. Adverse events attributable to the trial drugs medroxyprogesterone acetate and bezafibrate
- Secondary Outcome Measures
Name Time Method 1. Response to therapy<br>2. Disease-free survival <br>3. Overall survival <br><br>Follow-up to a minimum of a year.